Dr. Jack Cush reviews the news and journal articles from this past week on RheumNow.com. Take this week's RheumIQ and test your knowledge!
All News
RheumNow recentlty surveyed rheumatologists about Sjogren’s disease (SjD) - how they approach diagnosis, treatment, and unique challenges; all important as new advances in SjD evolves.
A EUVAS-sponsored expert panel of 37 specialists across rheumatology, nephrology, dermatology and pathology has published evidence-based guidelines for adult-onset IgA vasculitis (IgAV), which behaves very differently in adults compared to usually self-limited childhood form.
Registry Data Shows Liver Risk With Avacopan
A new study may add fuel to the fire already burning around avacopan (Tavneos), approved in 2021 to treat anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis (AAV), which the FDA wants drugmaker Amgen to pull from the U.S. market.
This review article addresses the recognition, prevention and management of glucocorticoid toxicity in rheumatic patients.
The rheumatology and scleroderma communities mourn the loss of Dr. Thomas A. Medsger Jr., who died August 15, 2026, in Pittsburgh, at age 89.
High fever, strange rashes, scary labs often lead to a consideration of Still's disease (AOSD or systemic JIA). Yet the dramatic onset of a systemic disorder may overlap with another, and possibly as rare, systemic disorder that should not be misdiagnosed or mistreated. A current case review by Zhu et al. presents six cases initially diagnosed as systemic JIA, teaching several important lessons.
EU Finalizes Tavneos Withdrawal - The European Commission has officially revoked the marketing authorization for Tavneos (avacopan), finalizing a process that began with regulators flagging the drug's pivotal trial data as "incorrect and misleading." The EC issued its legally https://t.co/jgysiV1hyX
